Previous 10 | Next 10 |
2024-03-12 13:00:03 ET Shagun Singh from RBC Capital issued a price target of $165.00 for DXCM on 2024-03-12 11:54:00. The adjusted price target was set to $165.00. At the time of the announcement, DXCM was trading at $134.475. The overall price target consensus is at $7...
2024-03-12 12:52:20 ET More on DexCom DexCom: A Wealth Compounder In Healthcare DexCom, Inc. (DXCM) Q4 2023 Earnings Call Transcript DexCom, Inc. 2023 Q4 - Results - Earnings Call Presentation FDA approves Dexcom's Stelo glucose monitor for OTC use Ti...
2024-03-10 13:00:53 ET More on the markets S&P 500: Time To Hedge, Here's How How The S&P 500 Could Actually Be Closer To 4,200 Than 5,000 SPDR S&P 500 ETF And Invesco QQQ Trust: Almost All Investors Are Crowded Into The Same Side Of The Boat Cata...
2024-03-08 09:15:00 ET A good way to invest in the healthcare industry's continued growth is by targeting businesses that make medical devices. Such equipment aids physicians in surgery, helps patients recover, and can assist people in staying on top of chronic conditions, including hyperte...
2024-03-08 08:43:37 ET More on Insulet Insulet Corporation (PODD) Q4 2023 Earnings Call Transcript Insulet: An Interesting, Yet Expensive, Story Insulet Non-GAAP EPS of $1.40 beats by $0.74, revenue of $509.8M beats by $48.74M Insulet Q4 2023 Earnings Preview...
2024-03-07 14:54:51 ET Summary iShares Russell Mid-Cap Growth ETF uses one valuation and two growth metrics to pick mid-cap stocks. The portfolio is well-diversified and quality metrics look good. The IWP ETF has recently outperformed competitors, and trading volumes can satis...
Stelo will be the first glucose biosensor in the US cleared for use without a prescription Indicated for use for people 18 years and older who are not using insulin therapy A small, wearable sensor worn on the back of the upper arm, Stelo will provide glucose insights directly to a user...
New data shows long-term use of an AID system powered by Dexcom CGM can safely maintain improvements in glycaemic outcomes for up to two years 1. Real-world evidence demonstrates reduction in severe hypoglycaemia and diabetic ketoacidosis over 12 months in people with Type 1 diabetes ...
2024-03-03 10:15:00 ET Looking for great stocks to buy in a bull market has its downsides. For instance, it's harder to find deep discounts during a bull run. However, that's not a big problem provided investors put their hard-earned money in companies that can perform well over the long ru...
2024-03-01 09:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
News, Short Squeeze, Breakout and More Instantly...
2024-07-04 10:00:00 ET Growth-oriented investors have experienced a bit of a roller-coaster ride over the past few years. Many companies in the "growth stock" category were struggling just two years ago, but in the bull market we are now experiencing, they're delivering very different resul...
DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2024 financial results after market close on Thursday, July 25, 2024. Management will hold a conference call to review the company's second quarter 2024 performance starting at 4:30 p.m. (Eastern Time) on the...